Robin Kate Kelley

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Robin Kate Kelley sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials none currently recruiting 2 completed early-phase tilt upper half by trial count

Robin Kate Kelley: 2 sponsored US clinical trials, none currently recruiting.

Robin Kate Kelley sponsors 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stage IIIC Hepatocellular Carcinoma AJCC v7, with 1 trials.

Mid-pack sponsor footprint

Robin Kate Kelley is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

How the Robin Kate Kelley early-phase archive is shaped

2 indexed studies, none listed as recruiting (0% open); 2 completed (100%).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Stage IIIC Hepatocellular Carcinoma AJCC v7 (1 trial), 7 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Robin Kate Kelley: archived-pipeline peers nationwide

Peers matched on 2 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Robin Kate Kelley sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60% Total trials Recruiting share Robin Kate Kelley1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health10xBio22nd Century Group23andMe3-C Institute for Social Development
Robin Kate Kelley sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Robin Kate Kelley sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Robin Kate Kelley page

2 registered trials is a research-attention snapshot, not an endorsement of Robin Kate Kelley or any single study.

  • None of Robin Kate Kelley's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Stage IIIC Hepatocellular Carcinoma AJCC v7 is the condition Robin Kate Kelley studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stage IIIC Hepatocellular Carcinoma AJCC v7 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Robin Kate Kelley pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.